Phase II Study of Combination of Hyper-CVAD and Ponatinib in Patients With Philadelphia (PH) Chromosome Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL)

Trial Profile

Phase II Study of Combination of Hyper-CVAD and Ponatinib in Patients With Philadelphia (PH) Chromosome Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Jul 2017

At a glance

  • Drugs Ponatinib (Primary) ; Cyclophosphamide; Cytarabine; Cytarabine; Dexamethasone; Doxorubicin; Filgrastim; Methotrexate; Methylprednisolone; Prednisone; Rituximab; Vincristine
  • Indications Acute lymphoblastic leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 25 Jun 2017 Results (n=64) presented at the 22nd Congress of the European Haematology Association.
    • 02 Jun 2017 Initially ponatinib 45 mg daily was given indefinitely beginning at cycle 2, Due to concern for vascular events, a protocol amendment was made in which, beginning in cycle 2, patients in complete response received 30mg daily and patients in complete molecular response received 15mg daily as reported by results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
    • 02 Jun 2017 Results (n=64) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top